Page 8 - Science Network News Today

India will treat a domestic COVID-19 vaccine "equally" with a prominent global one, even though the homegrown drug's efficacy has not been proven, and people will have no choice which they one they get, a top government vaccine official told Reuters.

AIPSN Demands DCGI Reconsider Approvals for Covaxin and Covishield 06/01/2021 A medic demonstrates the administration of Covaxin with a health worker during a dry run in Srinagar, January 2, 2021. Photo: PTI. The Drug Controller General of India’s (DCGI) decision to approve Serum Institute’s Covishield and Bharat Biotech’s Covaxin v vaccine candidates has provoked a firestorm of criticism in the scientific and medical communities. Following this, the All India People’s Scien...

All-India scientists network seeks re-consideration of vaccine approval Top Searches: Representative Image. (Reuters Photo) MUMBAI: A national network of 40 science movements, the All-India People’s Science Network (AIPSN), has criticized the central government’s hasty regulatory approvals for the Covid-19 vaccines, particularly for Covaxin developed by the Bharat Biotech. In an open statement the network has sought re-consideration of the approval for Covaxin, till the efficacy data is ava...

Criticism of India's approval of a local COVID-19 vaccine without proof of its efficacy grew on Wednesday after news that a regulatory panel ...

Criticism of India's approval of a local COVID-19 vaccine without proof of its efficacy grew on Wednesday after news that a regulatory panel approved the shot just one day after asking the vaccine maker for more evidence it would work.

January 6, 2021 The Delhi High Court on Wednesday allowed the Delhi Science Forum and the Society for Knowledge Commons to become intervenors in a landmark copyright case that threatens to block access to online websites Sci-Hub and LibGen, which provide free access to swathes of scientific and technical literature and articles. On December 21,2020 three publishing giants sued Sci-Hub and LibGen before the Delhi High Court. The lawsuit — which demands that the websites and their mirrors and s...

Coronavirus | Criticism of vaccine approval continues Updated: Updated: All India People’s Science Network condemns the “hasty regulatory approval” Share Article All India People’s Science Network condemns the “hasty regulatory approval” Joining the criticism of the government’s green light to COVID-19 vaccines, the All India People’s Science Network (AIPSN), a federation of popular science movements across the country, condemned the “hasty regulatory approval.” In a stat...

Ready for this week’s retirement investing pop quiz? In what kind of bonds should you invest the fixed income portion of your portfolio if you thought that a huge economic downturn was just around the corner—U.S. Treasurys or High-Grade Corporate Bonds? The standard answer from most financial planners is the former. Their theory, which certainly is plausible, is that during economic crashes investors dump all risky assets—including corporate bonds—in favor of the safety of U.S. Treasury...